modelTimololCombinations

Diagram of TimololCombinations

Extends from Pharmacolibrary.Drugs.ATC.S.S01ED51.

Information

name:TimololCombinations
ATC code:S01ED51
route:ophthalmic
compartments:1
dosage:0.5mg
volume of distribution:1.2L
clearance:0.8L/h/kg
other parameters in model implementation

Timolol is a non-selective beta-adrenergic antagonist primarily used for the reduction of intraocular pressure in the treatment of glaucoma. In the ATC group S01ED51, timolol is utilized in combination with other agents to enhance intraocular pressure-lowering efficacy. It is an approved medication and widely used in clinical ophthalmology today.

Pharmacokinetics

Estimated pharmacokinetic parameters for timolol in fixed-dose ophthalmic combinations in healthy adult patients, as specific PK profiles for combinations in published literature are limited. Based on pharmacokinetics of ophthalmic timolol exposures from referenced single-agent studies.

References

  1. Goldberg, I, et al., & Bejanian, M (2014). Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. The British journal of ophthalmology 98(7) 926–931. DOI:10.1136/bjophthalmol-2013-304064 PUBMED:https://pubmed.ncbi.nlm.nih.gov/24667994

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)